

CORRECTION

De Caterina R, Renda G, Carnicelli AP, Nordio F, Trevisan M, Mercuri MF, Ruff CT, Antman EM, Braunwald E, Giugliano RP

Valvular Heart Disease Patients on Edoxaban or Warfarin in the ENGAGE AF-TIMI 48 Trial


J Am Coll Cardiol 2017;69:1372-82.

On page 1378 in the Central Illustration, the interaction p value under the top panels read 0.44, but should have been 0.26.

The correct version of the Central Illustration is presented below.



CENTRAL ILLUSTRATION NOACs for VHD in Atrial Fibrillation: Stroke and Major Bleeding Events



De Caterina, R. et al. J Am Coll Cardiol. 2017;69(11):1372-82.

(Top panels) Kaplan-Meier curves for total stroke or systemic embolic event by randomized treatment group and VHD status, during the study period. (Bottom panels) Kaplan-Meier curves for major bleeding by randomized treatment group and VHD status during the study period. NOAC = non-vitamin K antagonist oral anticoagulant; SEE = systemic embolic event; VHD = valvular heart disease.

The authors apologize for this error.

The online version of the article has been corrected to reflect this change.

<https://doi.org/10.1016/j.jacc.2019.01.002>